Dr. Jean M. Tersak
Claim this profileChildren's Hospital of Pittsburgh of UPMC
Expert in Cancer
Expert in Uterine Tumors
43 reported clinical trials
99 drugs studied
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Uterine Tumors
Global LeaderStage I
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Jean M. Tersak is currently running
Triptorelin
for Cancer
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.
Recruiting2 awards Phase 34 criteria
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
More about Jean M. Tersak
Clinical Trial Related7 years of experience running clinical trials · Led 43 trials as a Principal Investigator · 14 Active Clinical TrialsTreatments Jean M. Tersak has experience with
- Etoposide
- Cyclophosphamide
- Cytology Specimen Collection Procedure
- Laboratory Biomarker Analysis
- Carboplatin
- Doxorubicin Hydrochloride
Breakdown of trials Jean M. Tersak has run
Cancer
Uterine Tumors
Neuroblastoma
Osteosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jean M. Tersak specialize in?
Jean M. Tersak focuses on Cancer and Uterine Tumors. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Jean M. Tersak currently recruiting for clinical trials?
Yes, Jean M. Tersak is currently recruiting for 8 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Jean M. Tersak has studied deeply?
Yes, Jean M. Tersak has studied treatments such as Etoposide, Cyclophosphamide, Cytology Specimen Collection Procedure.
What is the best way to schedule an appointment with Jean M. Tersak?
Apply for one of the trials that Jean M. Tersak is conducting.
What is the office address of Jean M. Tersak?
The office of Jean M. Tersak is located at: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania 15224 United States. This is the address for their practice at the Children's Hospital of Pittsburgh of UPMC.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.